These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 38648390)

  • 21. Experience with high-risk human papillomavirus testing on vaginal brush-based self-samples of non-attendees of the cervical screening program.
    Gök M; van Kemenade FJ; Heideman DA; Berkhof J; Rozendaal L; Spruyt JW; Beliën JA; Babovic M; Snijders PJ; Meijer CJ
    Int J Cancer; 2012 Mar; 130(5):1128-35. PubMed ID: 21484793
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Urine high-risk human papillomavirus testing as an alternative to routine cervical screening: A comparative diagnostic accuracy study of two urine collection devices using a randomised study design trial.
    Davies JC; Sargent A; Pinggera E; Carter S; Gilham C; Sasieni P; Crosbie EJ
    BJOG; 2024 Oct; 131(11):1456-1464. PubMed ID: 38660737
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening.
    Naucler P; Ryd W; Törnberg S; Strand A; Wadell G; Elfgren K; Rådberg T; Strander B; Forslund O; Hansson BG; Hagmar B; Johansson B; Rylander E; Dillner J
    J Natl Cancer Inst; 2009 Jan; 101(2):88-99. PubMed ID: 19141778
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Short-time repeat high-risk HPV testing by self-sampling for screening of cervical cancer.
    Gyllensten U; Sanner K; Gustavsson I; Lindell M; Wikström I; Wilander E
    Br J Cancer; 2011 Aug; 105(5):694-7. PubMed ID: 21811250
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples: a meta-analysis.
    Arbyn M; Verdoodt F; Snijders PJ; Verhoef VM; Suonio E; Dillner L; Minozzi S; Bellisario C; Banzi R; Zhao FH; Hillemanns P; Anttila A
    Lancet Oncol; 2014 Feb; 15(2):172-83. PubMed ID: 24433684
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Study protocol of the CHOiCE trial: a three-armed, randomized, controlled trial of home-based HPV self-sampling for non-participants in an organized cervical cancer screening program.
    Tranberg M; Bech BH; Blaakær J; Jensen JS; Svanholm H; Andersen B
    BMC Cancer; 2016 Nov; 16(1):835. PubMed ID: 27809810
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Triage by methylation-marker testing versus cytology in women who test HPV-positive on self-collected cervicovaginal specimens (PROHTECT-3): a randomised controlled non-inferiority trial.
    Verhoef VM; Bosgraaf RP; van Kemenade FJ; Rozendaal L; Heideman DA; Hesselink AT; Bekkers RL; Steenbergen RD; Massuger LF; Melchers WJ; Bulten J; Overbeek LI; Berkhof J; Snijders PJ; Meijer CJ
    Lancet Oncol; 2014 Mar; 15(3):315-22. PubMed ID: 24529697
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Study protocol of the ACCESS trial: a randomised trial to evaluate the effectiveness of human papillomavirus testing by self-sampling in cervical cancer screening uptake and precancer detection.
    Fujita M; Shimazu M; Nagashima K; Suzuki M; Tauchi I; Sakuma M; Yamamoto S; Shozu M; Hanaoka H; Tsuruoka N; Kasai T; Hata A
    BMJ Open; 2022 Feb; 12(2):e049803. PubMed ID: 35115348
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CyclinA1 Promoter Methylation in Self-Sampling Test.
    Oranratanaphan S; Kengsakul M; Triratanachat S; Kitkumthorn N; Mutirangura A; Termrungruanglert W
    Asian Pac J Cancer Prev; 2020 Oct; 21(10):2913-2917. PubMed ID: 33112548
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pooled analysis of a self-sampling HPV DNA Test as a cervical cancer primary screening method.
    Zhao FH; Lewkowitz AK; Chen F; Lin MJ; Hu SY; Zhang X; Pan QJ; Ma JF; Niyazi M; Li CQ; Li SM; Smith JS; Belinson JL; Qiao YL; Castle PE
    J Natl Cancer Inst; 2012 Feb; 104(3):178-88. PubMed ID: 22271765
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Protocol for Compass: a randomised controlled trial of primary HPV testing versus cytology screening for cervical cancer in HPV-unvaccinated and vaccinated women aged 25-69 years living in Australia.
    Canfell K; Saville M; Caruana M; Gebski V; Darlington-Brown J; Brotherton J; Heley S; Castle PE
    BMJ Open; 2018 Jan; 8(1):e016700. PubMed ID: 29374658
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High-risk HPV testing on self-sampled versus clinician-collected specimens: a review on the clinical accuracy and impact on population attendance in cervical cancer screening.
    Snijders PJ; Verhoef VM; Arbyn M; Ogilvie G; Minozzi S; Banzi R; van Kemenade FJ; Heideman DA; Meijer CJ
    Int J Cancer; 2013 May; 132(10):2223-36. PubMed ID: 22907569
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevalence of human papillomavirus genotypes and precancerous cervical lesions in a screening population in the Republic of Korea, 2014-2016.
    Ouh YT; Min KJ; Cho HW; Ki M; Oh JK; Shin SY; Hong JH; Lee JK
    J Gynecol Oncol; 2018 Jan; 29(1):e14. PubMed ID: 29185272
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Performance of self-collected cervical samples in screening for future precancer using human papillomavirus DNA testing.
    Porras C; Hildesheim A; González P; Schiffman M; Rodríguez AC; Wacholder S; Jiménez S; Quint W; Guillen D; Kreimer AR; Herrero R;
    J Natl Cancer Inst; 2015 Jan; 107(1):400. PubMed ID: 25479804
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test.
    Ronco G; Giorgi-Rossi P; Carozzi F; Confortini M; Dalla Palma P; Del Mistro A; Gillio-Tos A; Minucci D; Naldoni C; Rizzolo R; Schincaglia P; Volante R; Zappa M; Zorzi M; Cuzick J; Segnan N;
    J Natl Cancer Inst; 2008 Apr; 100(7):492-501. PubMed ID: 18364502
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Benefit and burden in the Dutch cytology-based vs high-risk human papillomavirus-based cervical cancer screening program.
    Loopik DL; Koenjer LM; Siebers AG; Melchers WJG; Bekkers RLM
    Am J Obstet Gynecol; 2021 Feb; 224(2):200.e1-200.e9. PubMed ID: 32800820
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Randomised healthcare policy evaluation of organised primary human papillomavirus screening of women aged 56-60.
    Lamin H; Eklund C; Elfström KM; Carlsten-Thor A; Hortlund M; Elfgren K; Törnberg S; Dillner J
    BMJ Open; 2017 May; 7(5):e014788. PubMed ID: 28566363
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of Mailed Human Papillomavirus Test Kits vs Usual Care Reminders on Cervical Cancer Screening Uptake, Precancer Detection, and Treatment: A Randomized Clinical Trial.
    Winer RL; Lin J; Tiro JA; Miglioretti DL; Beatty T; Gao H; Kimbel K; Thayer C; Buist DSM
    JAMA Netw Open; 2019 Nov; 2(11):e1914729. PubMed ID: 31693128
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Primary screening for high risk HPV by home obtained cervicovaginal lavage is an alternative screening tool for unscreened women.
    Nobbenhuis MA; Helmerhorst TJ; van den Brule AJ; Rozendaal L; Jaspars LH; Voorhorst FJ; Verheijen RH; Meijer CJ
    J Clin Pathol; 2002 Jun; 55(6):435-9. PubMed ID: 12037026
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of a high-risk human papillomavirus DNA test as the primary test in a cervical cancer screening programme: a population-based cohort study.
    Zorzi M; Del Mistro A; Farruggio A; de'Bartolomeis L; Frayle-Salamanca H; Baboci L; Bertazzo A; Cocco P; Fedato C; Gennaro M; Marchi N; Penon MG; Cogo C; Ferro A
    BJOG; 2013 Sep; 120(10):1260-7; discussion 1267-8. PubMed ID: 23786222
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.